News Releases

Company will leverage its proprietary vIgDTM platform using directed evolution to create novel, multi‐functional first in class immunotherapies SEATTLE, Wash., June 13, 2016 – Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next‐generation immune system

A biotechnology company in Seattle led by former Dendreon CEO Mitchell Gold has netted $48 million in funding, marking the region’s largest biotech funding so far this year. Alpine Immune Sciences was formed out of health-care investment fund Alpine BioVentures, also co-founded by Gold.

Mitch Gold will be forever known as the guy who led Dendreon on a controversial roller coaster ride in cancer immunotherapy. Now he’s moved on, and raised a big chunk of money for a startup called Alpine Immune Sciences . Seattle-based Alpine Immune Sciences is announcing today it has raised $48

Most biotechs go after a launch round and then look for a high-profile industry collaboration. But most biotechs aren’t run by Mitch Gold. The former Dendreon CEO and current venture capitalist has pieced together a $48 million A round for Alpine Immune Sciences in Seattle, which will now look to

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment ‐ Kite to Exclusively License Transmembrane Immunomodulatory Protein Technology for Applications to CAR and TCR Programs SANTA MONICA, Calif.

As former CEO of Seattle biotech Dendreon Corp. Mitchell Gold embarks on a new biotech immunotherapy company called Alpine Immune Sciences Inc. , how will he ensure it doesn’t meet the same fate as his prior company? Gold led Dendreon for nine years and stepped down in 2012.

Dendreon may be on its last legs , but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences , seeding about $1.3 million into the company through his investment firm, Alpine BioVentures .